Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis
Trial details
- Registry ID
- NCT05134441
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as Vidofludimus calcium; vidofludimus calcium
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple SclerosisNCT05134441 | Immunic AG | Phase 3 | Active not recruiting | 2026-11Estimated |
| Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple SclerosisNCT05201638 | Immunic AG | Phase 3 | Active not recruiting | 2026-11Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |